Myriad Brain Cancer Drug Advances to Phase II
Posted on: Thursday, 8 March 2007, 12:01 CST
Myriad Genetics has started the first phase II human clinical trial to determine the safety profile of brain cancer drug, Azixa.
The phase II trial is also designed to determine the extent of its ability to improve the survival of patients with glioblastoma multiforme, the most common form of primary brain cancer.
The first stage of the trial is designed to determine the safety and the maximum tolerated dose of Azixa in combination with oxaliplatin. The maximum tolerated dose of Azixa alone was determined during the earlier phase I trials. The second stage of the trial will then assess the survival of patients treated with the Azixa plus oxaliplatin compared to Azixa alone or oxaliplatin alone.
Azixa has a dual mode of action; it acts as a cytotoxin and a vascular disrupting agent (VDA). VDAs kills tumor cell by reducing the blood supply to a tumor.
"The ability of Azixa to cross the blood-brain barrier gives us hope that because it can reach the site of the disease, it could be a more effective therapeutic than anything available today," said Adrian Hobden, president of Myriad Pharmaceuticals.
Source: Datamonitor
Related Articles
- Algeta to Enroll US Patients Into Global Phase III ALSYMPCA Trial Following Successful End-of-Phase II Meeting With FDA
- Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
- MorphoSys Files Clinical Trial Application to Initiate First Phase 1 Clinical Study of Its MOR103 Program
- XenoPort Announces Results of a Phase 1 Clinical Trial and Plans for Additional Phase 2 Clinical Trials of XP19986
- Amorcyte Cardiac Cell Therapy Trial Completes Second of Four Phases
- Marshall Edwards, Inc. Announces Initial Trial Sites, Principle Investigator for Phase III OVATURE Trial for Phenoxodiol
- BEMA(TM) LA Achieves Therapeutic Plasma Concentrations in Phase I Trial: Complementary Pain Therapy to Phase III BEMA(TM) Fentanyl Product
- AVI BioPharma Provides Update on Hepatitis C Virus Clinical Trial Status; Data From the Phase I/II Accepted for Oral Platform Presentation at ICAR
- Regeneron Completes Enrollment for IL-1 Trap Phase 3 Trial in Autoinflammatory Disease; Efficacy Phase of Trial on Target for Completion in 2006
- Moussaoui Trial to Move Into Next Phase
 |
 |
User Comments (0)
RSS Feeds